EDINBURGH, Scotland, Sept. 9,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC
("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical
stage biotechnology company developing platform allogeneic
gamma-delta T cell therapies for cancer and other indications,
today announced that it intends to begin Proof of Concept
preclinical studies for its lead therapeutic TCB 008, for treatment
in monkey pox.
TCB008 is an allogeneic unmodified cell therapy that is made up
of activated and expanded gamma delta T (GDT) cells which the
company expects will have applications in treating the global
health emergency. Due to the highly infectious nature of monkeypox,
TCBP expects to partner with a leading Infectious Disease Center or
University associated with a similar organization to rapidly
advance the Proof-of-Concept and pre-clinical studies.
"There are a number of academic papers highlighting a successful
immune response to viral infection being heavily reliant on the
presence of gamma delta t-cells," commented CEO Bryan Kobel. "We continue to look at avenues to
expand the therapeutic applications for TCB008 and moving into
rapid response for aggressive viral infections is an arena we
believe our therapeutic can be immediately impactful. The ability
to deliver a frozen/thawed product to these patients to prevent not
just the death or extended viral infection in these patients, but
also potentially slow the spread of the infectious disease and
contain the issue from becoming a global pandemic, would represent
a massive global opportunity and market size. We look forward to
updating investors as we further this program."
Mpox (monkeypox) is a viral illness caused by a species of the
genus Orthopoxvirus. Two different clades exist: clade I and clade
II. Common symptoms of the virus are a skin rash or mucosal lesions
which can last 2–4 weeks accompanied by fever, headache, muscle
aches, back pain, low energy, and swollen lymph nodes. The disease
can be transmitted to humans through physical contact with someone
who is infectious, with contaminated materials, or with infected
animals. In 2022–2023 a global outbreak of mpox was caused by a
strain known as clade IIb.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the Company's intent or ability to affect any
budget savings or execute on any M&A or capital raising
strategy. These statements are based on management's current
assumptions and are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this Current Report
on Form 8-K. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid
leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-intends-to-launch-preclinical-studies-for-treatment-of-monkey-pox-302241204.html
SOURCE TC BioPharm